Headlines about Kadmon (NYSE:KDMN) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kadmon earned a news impact score of 0.15 on Accern’s scale. Accern also assigned media stories about the company an impact score of 44.6434326106034 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news headlines that may have impacted Accern Sentiment’s scoring:
- Kadmon Holdings, Inc. (NYSE:KDMN) – Analysts’ Suggestions in the Limelight – Nasdaq Journal (nasdaqjournal.com)
- Investor is seeking for stock with consensus Analysts Rating? Kadmon Holdings, Inc. (KDMN) – Wall Street Morning (wallstreetmorning.com)
- Kadmon Holdings, Inc., (NYSE: KDMN) – How Much Percent Do The Stock More or Less Volatile Than The Market? – Stock Watch (stocksnewstimes.com)
- Kadmon Holdings, Inc. (KDMN) – Focus on Unusual Volume Activity – Wall Street Morning (wallstreetmorning.com)
- Kadmon (KDMN) Rating Increased to Hold at Zacks Investment Research (americanbankingnews.com)
Kadmon (NYSE:KDMN) traded up $0.02 during mid-day trading on Wednesday, hitting $4.26. The stock had a trading volume of 119,243 shares, compared to its average volume of 1,127,146. The stock has a market capitalization of $337.38, a PE ratio of -2.85 and a beta of 5.59. Kadmon has a 52-week low of $2.05 and a 52-week high of $5.86.
A number of analysts have recently issued reports on KDMN shares. Zacks Investment Research downgraded Kadmon from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Jefferies Group lifted their price target on Kadmon to $16.00 and gave the stock a “buy” rating in a research note on Tuesday, February 13th. Piper Jaffray Companies reissued a “positive” rating and set a $9.00 target price (up from $7.00) on shares of Kadmon in a research note on Tuesday, February 13th. Finally, HC Wainwright restated a “buy” rating and set a $25.00 price target on shares of Kadmon in a research report on Friday, March 9th. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. Kadmon has a consensus rating of “Hold” and an average price target of $10.21.
TRADEMARK VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Kadmon (NYSE:KDMN) Stock Price” was originally reported by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The original version of this news story can be read at https://baseballnewssource.com/2018/03/14/kadmon-kdmn-earning-somewhat-favorable-media-coverage-study-shows/1923639.html.
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.